Intraerythrocytic Iron Chelation: A New Therapy for Thalassemia?

References

• Weatherall, D. J. and Clegg, J. B. (1996). Thalassemia—a global public health problem, Nat Med, 2, 847–849.
   PubMed Web of Science ®Google Scholar
• Weatherall, D. J. and Clegg, J. B. (1969). The pattern of disordered haemoglobin synthesis in homozygous andheterozygous β-thalassaemia, Br J Haemat, 16, 251–267.
   PubMed Web of Science ®Google Scholar
• Ritchey, A. K., Hoffman, R., Coupal, E., Floyd, V., Pearson, H. A. and Forget, B. G. (1981). Imbalanced globin chain synthesis in cultured erythroid progenitor cells from thalassemic bone marrow and peripheral blood, Blood, 57, 788–793.
   PubMed Web of Science ®Google Scholar
• Schwartz, E. (1974). Abnormal globin synthesis in thalassemic red cells, Semin Hematol, 11, 549–567.
   PubMed Web of Science ®Google Scholar
• Vigi, V., Volpato, S. Gaburro, D., Conconi, F., Bargellesi, A. and Pontremoli, S. (1969). The correlation between red-cell survival and excess of α-globin synthesis in β-thalassaemia, Br J Haemat, 16, 25–30.
   PubMed Web of Science ®Google Scholar
• Blendis, L. M., Modell, C. B., Bowdler, A. J. and Williams, R. (1974). Some effects of splenectomy in thalassaemia major, Br J Haematol, 28, 77–87.
   PubMed Web of Science ®Google Scholar
• Pippard, M. J. (1994). Secondary iron overload. In Iron Metabolism in Health & Disease, edited by J. H. Brock, J. W. Halliday, M. J. Pippard and L. W. Powell, pp. 271–309, London. W. B. Saunders.
   Google Scholar
• Beard, M. E., Necheles, T. F. and Allen, D. M. (1967). Intensive transfusion therapy in thalassemia major, Pediatrics, 40, 911–915.
   PubMed Web of Science ®Google Scholar
• Piomelli, S., Danoff, S. J., Becker, M. H., Lipera, M. J. and Travis, S. F. (1969). Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen, Ann N Y Acad Sci, 165, 427–436.
   PubMed Web of Science ®Google Scholar
• Pearson, H. A. and O'Brien, R. T. (1975). The management of thalassemia major, Semin Hematol, 12, 255–265.
   PubMed Web of Science ®Google Scholar
• Piomelli, S., Karpatkin, M. H., Arzanian, M., Zamani, M., Becker, M. H., Geneiser, N., Danoff, S. J. and Kuhns, W. J. (1974). Hypertransfusion regimen in patients with Cooley's anemia, Ann N Y Acad Sci, 232, 186–192.
   PubMed Web of Science ®Google Scholar
• Bannerman, R. M., Keusch, G., Kreimer-Birnbaum, M., Vance, V. K. and Vaughan, S. (1967). Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria, Am J Med, 42, 476–486.
   PubMed Web of Science ®Google Scholar
• Orsini, A., Giraud, F., Bernard, P. and Passeron, P. (1965). Use of desferrioxamine B in the treatment of post-transfusion hypersiderosis, Mars Med, 102, 591–595.
   PubMedGoogle Scholar
• Propper, R. D., Shurin, S. B. and Nathan, D. G. (1976). Reassessment of the use of desferrioxamine B in iron overload, N Engl J Med, 294, 1421–1423.
   PubMed Web of Science ®Google Scholar
• Whitten, C. F., Gibson, G. W., Good, M. H., Goodwin, J. F. and Brough, A. J. (1965). Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations, Pediatrics, 36, 322–335.
   PubMed Web of Science ®Google Scholar
• Summers, M. R., Jacobs, A., Tudway, D., Perera, P. and Ricketts, C. (1979). Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects, Br J Haematol, 42, 547–555.
   PubMed Web of Science ®Google Scholar
• Hallaway, P. E., Eaton, J. W., Panter, S. S. and Hedlund, B. E. (1989). Modulation of deferoxamine toxicityand clearance by covalent attachment to biocompatible polymers, Proc Natl Acad Sci USA, 86, 10108–10112.
   PubMed Web of Science ®Google Scholar
• Olivieri, N. F. and Brittenham, G. M. (1997). Iron-chelating therapy and the treatment of thalassemia, Blood, 89, 739–761.
   PubMed Web of Science ®Google Scholar
• Olivieri, N. F., Buncic, J. R., Chew, E., Gallant, T., Harrison, R. V., Keenan, N., Logan, W., Mitchell, D., Ricci, G. and Skarf, B. (1986). Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions, N Engl J Med, 314, 869–873.
   PubMed Web of Science ®Google Scholar
• Giardina, P. J. and Grady, R. W. (1995). Chelation therapy in β-thalassemia: the benefits and limitations of desferrioxamine, Semin Hematol, 32, 304–312.
   PubMed Web of Science ®Google Scholar
• Olivieri, N. F. (1996). Long-term therapy with defiprone, Acta Haematol, 95, 37–48.
   PubMed Web of Science ®Google Scholar
• Jacob, H. S. and Lux, S. E. (1968). Degradation of membrane phospholipids and thiols in peroxide hemolysis. Studies in vitamin E deficiency, Blood, 32, 549–568.
   PubMed Web of Science ®Google Scholar
• Kuross, S. A. and Hebbel, R. P. (1988). Nonheme iron in sickle erythrocyte membranes: Association with phospholipids and potential role in lipid peroxidation, Blood, 72, 1278–1285.
   PubMed Web of Science ®Google Scholar
• Weed, R. (1970). The importance of erythrocyte deformability, Am J Med, 49, 147–150.
   PubMed Web of Science ®Google Scholar
• Scott, M. D., Rouyer-Fessard, P., Ba, M. S., Lubin, B. H. and Beuzard, Y. (1992). α- and β-haemoglobin chain induced changes in normal erythrocyte deformability: Comparison to β thalassaemia intermedia and HbH disease, Br J Haem, 80, 519–526.
   PubMed Web of Science ®Google Scholar
• Smith, K. A. and Mengel, C. E. (1968). Association of iron dextran induced hemolysis and lipid peroxidationin mice, J Lab Clin Med, 72, 505–510.
   PubMed Web of Science ®Google Scholar
• Rachmilewitz, E. A. (1976). The role of intracellular hemoglobin precipitation, low MHCH, and iron overloadon red blood cell membrane peroxidation in thalassemia, Birth Defects: Original Articles Series, 12(8), 123–133.
   PubMedGoogle Scholar
• Kahane, I. and Rachmilewitz, E. A. (1976). Alterations in the red cell membrane and the effect of vitamin E on osmotic fragility in β-thalassemia major, Isr J Med Sci, 12, 11–15.
   PubMedGoogle Scholar
• Wallace, W. J. and Caughey, W. S. (1979). Superoxide as a participant in the chemistry of oxyhemoglobin. In Biochemical and Clinical Aspects of Oxygen, edited by W.S. Caughey, p. 69, New York. Academic Press.
   Google Scholar
• Yataganas, X. and Fessas, P. (1969). The pattern of hemoglobin precipitation in thalassemia and its significance, Ann NY Acad Sci, 165, 270–277.
   PubMed Web of Science ®Google Scholar
• Cividalli, G., Kerem, H. and Rachmilewitz, E. A. (1980). Globin synthesis in severe and intermediate homozygous β-thalassemia in Israel, Ann NY Acad Sci, 344, 132–140.
   PubMedGoogle Scholar
• Weatherall, D. J. and Clegg, J. B. (1973). The Thalassaemia Syndromes, 2nd edn, Oxford. Blackwell Scientific Publications.
   Google Scholar
• Scott, M. D., Rouyer-Fessard, P., Lubin, B. H. and Beuzard, Y. (1990). Entrapment of purified α-hemoglobin chains in normal erythrocytes: A model for β thalassemia, J Biol Chem, 265, 17953–17959.
   PubMed Web of Science ®Google Scholar
• Bunn, H. F. and Jandl, J. H. (1967). Exchange of heme among hemoglobins and between hemoglobin and albumin, J Biol Chem, 243, 465–475.
   Web of Science ®Google Scholar
• Hebbel, R. P., Eaton, J. W., Balasingam, M. and Steinberg, M. H. (1982). Spontaneous oxygen radical generation by sickle erythrocytes, J Clin Invest, 70, 1253–1259.
   PubMed Web of Science ®Google Scholar
• Scott, M. D., van den Berg, J. J. M., Repka, T., Rouyer-Fessard, P., Hebbel, R. P., Beuzard, Y. and Lubin, B. H. (1993). Effect of excess α-hemoglobin chains on cellular and membrane oxidation in model β thalassemic erythrocytes, J Clin Invest, 91, 1706–1712.
   PubMed Web of Science ®Google Scholar
• Scott, M. D. and Eaton, J. W. (1995). Thalassaemic erythrocytes: Cellular suicide arising from iron and glutathione-dependent oxidation reactions? Br J Haem, 91, 811–819.
   PubMed Web of Science ®Google Scholar
• Scott, M. D., Yang, L., Ulrich, P. and Shupe, T. (1997). Pharmacologic interception of heme: a potential therapeutic strategy for the treatment of β thalassemia? Redox Report, 3, 159–167.
   PubMed Web of Science ®Google Scholar
• Kuypers, F. A., Schott, M. A. and Scott, M. D. (1996). Phospholipid composition in model β thalassemic erythrocytes, Am J Hematol, 51, 45–54.
   PubMed Web of Science ®Google Scholar
• Kuross, S. A., Rank, B. H. and Hebbel, R. P. (1988). Excess heme in sickle erythrocyte inside-out membranes: Possible role in thiol oxidation, Blood, 72, 876–882.
   Google Scholar
• Kuross, S. A., Rank, B. H. and Hebbel, R. P. (1989). Iron compartments associated with sickle RBC membranes: A mechanism for the targeting of oxidative damage. In The Red Cell: Seventh Ann Arbor Conference, edited by G. J. Brewer and J. W. Eaton, pp. 601–613, A.R. Liss, New York.
   Google Scholar
• Rank, B. H., Carlsson, J. and Hebbel, R. P. (1985). Abnormal redox status of membrane-protein thiols in sickle erythrocytes, J Clin Invest, 75, 1531–1537.
   PubMed Web of Science ®Google Scholar
• Repka, T. and Hebbel, R. P. (1991). Hydroxyl radical formation by sickle erythrocyte membranes: Role of pathologic iron deposits and cytoplasmic reducing agents, Blood, 78, 2753–2758.
   PubMed Web of Science ®Google Scholar
• Repka, T., Shalev, O., Reddy, R., Yuan, J., Abrahamov, A., Rachmilewitz, E. A., Low, P. S. and Hebbel, R. P. (1993). Nonrandom association of free iron with membranes of sickle and β-thalassemic erythrocytes, Blood, 82, 3204–3210.
   PubMed Web of Science ®Google Scholar
• Pickart, L. and Thaler, M. (1980). Growth-modulating tripeptide (Glycylhistidyllysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptidemetal ion complexes, J Cellular Physiol, 102, 129–139.
   PubMed Web of Science ®Google Scholar
• Pickart, L. and Lovejoy, S. (1987). Biological activity of human plasma copper-binding growth factor glycyl-L-histidyl-L-lysine, Methods in Enzymology, 147, 314–328.
   PubMed Web of Science ®Google Scholar
• Peterson, C. M., Graziano, J. H., Grady, R. W., Jones, R. L., Vlassara, H. V., Canale, V. C., Miller, D. R. and Cerami, A. (1976). Chelation studies with 23-dihydroxy-benzoic acid in patients with β-thalassaemia major, Br J Haemat, 33, 477–485.
   PubMed Web of Science ®Google Scholar
• Grady, R. W., Graziano, J. H., White, G. P., Jacobs, A. and Cerami, A. (1978). The development of new iron-chelating drugs, II, J Pharmacol Exp Ther, 205, 565–575.
   Web of Science ®Google Scholar
• Peterson, C. M., Graziano, J. H., Grady, R. W., Jones, R. L., Markenson, A., Lavi, U., Canale, V., Gray, G. F., Cerami, A. and Miller, D. R. (1979). Chelation therapy in β-thalassemia major: a one-year double blind study of 2,3-dihydroxybenzoic acid, Exp Hematol, 7, 74–80.
   PubMed Web of Science ®Google Scholar
• Brittenham, G. M. (1990). Pyridoxal isonicotinoyl hydrazone: An effective iron-chelator after oral administration, Seminars in Hematology, 27, 112–116.
   PubMed Web of Science ®Google Scholar
• Baker, E. (1988). Biologic screens for iron chelators, Birth Defects, 23, 49–61.
   PubMedGoogle Scholar
• Ponka, P., Grady, R. W., Wilczynska, A. and Schulman, H. M. (1984). The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone, Biochim Biophys Acta, 802, 477–489.
   PubMed Web of Science ®Google Scholar
• Richardson, D. R., Tran, E. H. and Ponka, P. (1995). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, Blood, 86, 4295–4306.
   PubMed Web of Science ®Google Scholar
• Richardson, D. R. and Ponka, P. (1998). Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease, J Lab Clin Med, 131, 306–315.
   PubMed Web of Science ®Google Scholar
• Blaha, K., Cikrt, M., Nerudova, J., Fomuskova, H. and Ponka, P. (1998). Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone, Blood, 91, 4368–4372.
   PubMed Web of Science ®Google Scholar
• Bergeron, R. J., Wiegand, J. and Brittenham, G. M. (1998). HBED: A potential alternative to deferoxamine for iron-chelating therapy, Blood, 91, 1446–1452.
   PubMed Web of Science ®Google Scholar
• Bergeron, R. J., Wiegand, J. and Brittenham, G. M. (1999). HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy, Blood, 93, 370–375.
   PubMed Web of Science ®Google Scholar
• van Zyl, R. L., Havlik, I., Hempelmann, E., MacPhail, A. P. and McNamara, L. (1993). Malaria pigment and extracellular iron. Possible target for iron chelating agents, Biochem Pharmacol, 45, 1431–1436.
   PubMed Web of Science ®Google Scholar
• Breuer, W., Epsztejn, S. and Cabantchik, Z. I. (1995). Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II), J Biol Chem, 270, 24209–24215.
   PubMed Web of Science ®Google Scholar
• Lund, L. G. and Aust, A. E. (1990). Iron mobilization from asbestos by chelators and ascorbic acid, Arch Biochem Biophys, 278, 61–64.
   PubMed Web of Science ®Google Scholar
• Chevion, M. (1991). Protection against free radical-induced and transition metal-mediated damage: the use of “pull” and “push” mechanisms, Free Radic Res Commun, 12–13 (part 2), 691–696.
   PubMedGoogle Scholar
• Hider, R. C., Singh, S., Porter, J. B. and Huehns, E. R. (1990). The development of hydroxypyridin-4-ones as orally active iron chelators, Ann N Y Acad Sci, 612, 327–338.
   PubMed Web of Science ®Google Scholar
• Shalev, O., Repka, T., Goldfarb, A., Grinberg, L., Abrahamov, A., Olivieri, N. F., Rachmilewitz, E. A. and Hebbel, R. P. (1995). Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo, Blood, 86, 2008–2013.
   PubMed Web of Science ®Google Scholar
• Hartley, A. and Rice-Evans, C. (1992). The chelation of nonheme iron within sickle erythrocytes by the hydroxy-pyridinone chelator CP094, Arch Biochem Biophys, 297, 377–382.
   PubMed Web of Science ®Google Scholar
• Olivieri, N. F., Brittenham, G. M., McLaren, C. E., Templeton, D. M., Cameron, R. G., McClelland, R. A., Burt, A. D. and Fleming, K. A. (1998). Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major, N Engl J Med, 339, 417–423.
   PubMed Web of Science ®Google Scholar
• Scott, M. D., Yang, L., Ulrich, P. and Shupe, T. (1997). Pharmacologic interception of heme: a potential therapeutic strategy for the treatment of β thalassemia? Redox Report, 3, 159–167.
   PubMed Web of Science ®Google Scholar
• Visca, P., Ciervo, A., Sanfilippo, V. and Orsi, N. (1993). Iron-regulated salicylate synthesis by Pseudomonas spp., J Gen Microbiol, 139, 1995–2001.
   PubMedGoogle Scholar
• Dinis, T. C., Maderia, V. M. and Almeida, L. M. (1994). Action of phenolic derivatives (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers, Arch Biochem Biophys, 315, 161–169.
   PubMed Web of Science ®Google Scholar
• Zanocco, A. L., Pavez, R., Videla, L. A. and Lissi, E. A. (1989). Antioxidant capacity of diethyldithiocarbamate in a metal independent lipid peroxidative process, Free Radio Biol Med, 7, 151–156.
   PubMed Web of Science ®Google Scholar
• Meshnick, S. R., Scott, M. D., Lubin, B. H., Ranz, A. and Eaton, J. W. (1990). The antimalarial activity of diethyldithiocarbamate: Potentiation by copper, Biochem Pharm, 40, 213–216.
   PubMed Web of Science ®Google Scholar
• Boyd, V. L., Harbell, J. W., O'Connor, R. J. and McGown, E. L. (1989). 2,3-Dithioerythritol, a possible newarsenic antidote, Chem Res Toxicol, 2, 301–306.
   PubMed Web of Science ®Google Scholar
• Sartiano, G. P., Levine, G. and Boggs, S. S. (1980). Influence of dimercaprol (2,3-dimercapto-1-propanol) on the pharmacokinetics of 111In-bleomycin in the P1798 lymphoma-bearing BALB/c mouse, Oncology, 37, 120–124.
   PubMed Web of Science ®Google Scholar
• Akanmu, D., Cecchini, R., Aruoma, O. I. and Halliwell, B. (1991). The antioxidant action of ergothioneine, Arch Biochem Biophys, 288, 10–16.
   PubMed Web of Science ®Google Scholar
• River, Y., Honigman, S., Gomori, J. M. and Reches, A. (1994). Superficial hemosiderosis of the central nervous system, Mov Disord, 9, 559–562.
   PubMed Web of Science ®Google Scholar
• Muller, U. and Krieglstein, J. (1995). Prolonged pretreatment with α-lipoic acid protects cultured neurons against hypoxic, glutamate-, or iron-induced injury, J Cereb Blood Flow Metab, 15, 624–630.
   PubMed Web of Science ®Google Scholar
• Hershko, C., Grady, R. W. and Link, G. (1982). Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug, Br J Haematol, 51, 251–260.
   PubMed Web of Science ®Google Scholar
• Hershko, C., Grady, R. W. and Link, G. (1984). Phenolic ethylenediamine derivatives: a study of orally effective iron chelators, J Lab Clin Med, 103, 337–346.
   PubMed Web of Science ®Google Scholar
• Ewe, K. (1968). Modification of iron absorption in the small intestine by complex formation with 8-hydroxyquinoline and its sulfonate. Perfusion studies of the human jejunum, Klin Wochenschr, 46, 296–300.
   PubMedGoogle Scholar
• Scott, M. D., Kuypers, F. A., Bütikofer, P., Bookchin, R. M., Ortiz, O. and Lubin, B. H. (1990). Effect of osmotic lysis and resealing on red cell structure and function, J Lab Clin Med, 115, 470–480.
   PubMed Web of Science ®Google Scholar
• Scott, M. D. (1992). Entrapment of purified α-hemoglobin chains in normal erythrocytes as a model of human β thalassemia. In The Use of Resealed Erythrocytes as Carriers and Bioreactors, edited by M. Magnani and J. R. DeLoach, pp. 139–148, New York. Plenum.
   Google Scholar
• Browne, P. V., Shalev, O., Kuypers, F. A., Brugnara, C., Solovey, A., Mohandas, N., Schrier, S. L. and Hebbel, R. P. (1997). Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia, J Clin Invest, 100, 1459–1464.
   PubMed Web of Science ®Google Scholar